Entera Bio (ENTX) Osake Kurssi

Entera Bio Ltd is primarily active in the biotechnology and pharmaceutical industries.

Some of the main competitors of Entera Bio Ltd in the market include Amgen Inc., Eli Lilly and Company, and Novartis AG. These companies are also involved in the development and commercialization of innovative biopharmaceutical products.

Entera Bio Ltd. is a biotechnology company that specializes in the development and commercialization of oral peptide drugs. Founded in 2010, Entera Bio is headquartered in Jerusalem, Israel. The company's proprietary oral delivery technology, known as the Peptide Absorption Technology (PAT), enables the oral administration of peptides, which are usually administered through injections. This innovative approach has the potential to revolutionize the treatment of various diseases and conditions. Entera Bio has a robust pipeline of oral drug candidates targeting different therapeutic areas, including osteoporosis, hypoparathyroidism, and non-alcoholic steatohepatitis (NASH). With its cutting-edge technology and strong focus on research and development, Entera Bio aims to improve patient outcomes and provide innovative solutions in the field of oral peptide therapeutics.

Entera Bio Ltd has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for its lead product, EB613, a novel oral parathyroid hormone (PTH) tablet for the treatment of osteoporosis and hypoparathyroidism. Entera Bio also obtained positive results from a pharmacokinetic study for EB612, an oral recombinant human parathyroid hormone (rhPTH(1-34)) for the treatment of hypoparathyroidism. Furthermore, the company recently announced a strategic collaboration with Amgen to develop and commercialize oral PTH treatments. These milestones highlight Entera Bio's progress in developing innovative oral drug delivery solutions, positioning the company as a leader in the field of oral PTH therapies.

Entera Bio Ltd is primarily present in the United States and Israel.

Entera Bio Ltd is committed to developing innovative therapies for various gastrointestinal diseases. With a focus on oral drug delivery, the company aims to improve patients' quality of life by providing convenient treatment options. Entera Bio values scientific excellence and strives to deliver effective solutions through its proprietary technology platform. The company's corporate philosophy centers around patient-centricity, continuous research and development, and fostering collaborations with key industry partners. With a strong commitment to clinical advancement and a steadfast dedication to enhancing therapeutic outcomes, Entera Bio Ltd aims to make a positive impact in the field of gastrointestinal healthcare.

Analyytikot asettavat tällä hetkellä Entera Bio-osakkeelle keskimääräisen tavoitehinnan 6,12 USD (mediaani: 6,12 USD), mikä merkitsee +141,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.

Entera Bio Analyytikkojen kursstavoitteet 2026

7 analyytikkoa arvioi tällä hetkellä Entera Bio-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä.

Entera Bio Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Entera Bio-osake noteerataan hintaan 2,26 EUR (2,53 USD).

Entera Bio-osake (ENTX) on listattuna 3 pörssissä, muun muassa: NASDAQ (ENTX), Frankfurt (5DT.F), Düsseldorf (5DT.DU).

Enter Bio Ltd is a biopharmaceutical company specializing in the development and marketing of innovative oral peptide therapies. The company's business model is based on the goal of increasing the therapeutic possibilities of peptides through the development of an oral formulation. This utilizes the benefits of peptide therapy, such as high effectiveness and low toxicity, while bypassing the difficulty of using peptides as injectable drugs. Enter Bio has three different business areas: drug development, active substance manufacturing, and licensing and partnerships. In drug development, innovative peptide-based medications for diseases in the areas of osteoporosis, diabetes, and HIV are being developed. Enter Bio works closely with many academic institutions and industry partners to utilize and further develop innovative technologies for peptide development and oral medication manufacturing. Another important business area of Enter Bio is active substance manufacturing. The company has a patented technology for peptide manufacturing and oralization, which allows for the production of peptides with high purity and effectiveness. This enables the company to meet the demand for drug active substances in the field of peptide therapy. Enter Bio also offers licensing and partnerships for partners who want to develop and market their own patents and take advantage of Enter Bio's patented technologies. Enter Bio operates an open and flexible licensing policy to ensure a wider use of oral peptide therapeutics. An important product of Enter Bio is the peptide therapy EB613 for osteoporosis. It is an oralization platform that allows the oral administration of the peptide PTH 1-34, a known anabolic agent for the treatment of osteoporosis. This medication can be an alternative to the currently available injectable medications, which is particularly beneficial for patients. Another important product of Enter Bio is EB612 for diabetes. This is an oral GLP-1 peptide agonist developed as an alternative to injectable peptide agonists for the treatment of diabetes. Unlike other orally absorbable peptides, EB612 has higher stability and a longer half-life, improving the effectiveness and compliance of the therapy. In summary, Enter Bio Ltd is an advanced biopharmaceutical company specializing in the development of oral peptide therapies. The company has built a unique technology platform that allows for the successful formulation, production, and marketing of peptides in oral medications. By offering innovative peptide therapeutics for osteoporosis, diabetes, and HIV, as well as services for active substance manufacturing and licensing and partnerships, Enter Bio contributes to creating new possibilities for the treatment of serious diseases and improving the quality of life for patients.

Liikevaihtoa ei voida laskea Entera Bio:lle tällä hetkellä.

odotettu voitto Entera Bio on −12,42 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Entera Bio:n hinta-voitto-suhde (P/E) on tällä hetkellä −9,41. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Entera Bio-osakkeen arvostusta.

P/S-suhdetta ei voida laskea Entera Bio:lle tällä hetkellä.

Entera Bio:n Eulpool-laatuscore on 2/10.

Entera Bio:n ISIN on IL0011429839. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Entera Bio:n WKN on A2JQXP. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Entera Bio:n ticker on ENTX. Tämä pörssinoteeraus käytetään Entera Bio-osakkeiden kauppaan pörssissä.